ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Novavax, Inc." (NVAX) Report Updated: Jul 25, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Novavax, Inc." (NVAX)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Biotechnology
Competitors: SPHS,ATHX,FPRX,DMPI

Stock Analysis

Rating: Monthly View

A
B
C
D
F
July August September October November December January February March April May June

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"Novavax, Inc."© quotemedia

Company Profile

Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase II clinical trials, as well as pediatric respiratory syncytial virus candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase I clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate, which is pre-clinical trial; and seasonal influenza vaccine candidate that is Phase III clinical trial, as well as rabies G protein vaccine candidate, which is in Phase 1/2 clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. has a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Gaithersburg, Maryland.